# Romark Laboratories L.C. clinical trials: 29 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials with Romark Laboratories L.C. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Romark Laboratories L.C.: 29 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/romark-laboratories-l-c

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 14, 2021 | NCT05157269 | Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness | Romark Laboratories L.C. | Phase 3 | Withdrawn | COVID-19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05157269) |
| December 14, 2021 | NCT05157243 | Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness | Romark Laboratories L.C. | Phase 3 | Withdrawn | COVID-19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05157243) |
| July 28, 2020 | NCT04489381 | Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection | Romark Laboratories L.C. | Phase 3 | Terminated | Enterovirus, Rhinovirus | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04489381) |
| July 24, 2020 | NCT04486313 | Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19 | Romark Laboratories L.C. | Phase 3 | Completed | COVID-19 | 935 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04486313) |
| April 24, 2020 | NCT04359680 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral... | Romark Laboratories L.C. | Phase 3 | Completed | COVID-19, Viral Respiratory Illnesses | 1,407 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04359680) |
| April 13, 2020 | NCT04343248 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory... | Romark Laboratories L.C. | Phase 3 | Terminated | COVID-19, Viral Respiratory Illnesses | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04343248) |
| April 5, 2019 | NCT03905655 | Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B | Romark Laboratories L.C. | Phase 2 | Completed | Chronic Hepatitis B | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03905655) |
| July 30, 2018 | NCT03605862 | Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection | Romark Laboratories L.C. | Phase 3 | Completed | Enterovirus, Rhinovirus | 1,756 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03605862) |
| November 8, 2017 | NCT03336619 | A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of... | Romark Laboratories L.C. | Phase 3 | Completed | Influenza | 1,030 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03336619) |
| November 24, 2015 | NCT02612922 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza | Romark Laboratories L.C. | Phase 3 | Completed | Influenza | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02612922) |
| June 1, 2012 | NCT01610245 | Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza | Romark Laboratories L.C. | Phase 3 | Completed | Influenza | 1,941 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01610245) |
| April 5, 2011 | NCT01328925 | Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children | Romark Laboratories L.C. | Phase 2 | Completed | Rotavirus Infection, Viral Gastroenteritis Due to Rotavirus | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01328925) |
| March 30, 2011 | NCT01326338 | Nitazoxanide for the Treatment of Prolonged Diarrhea in Children | Romark Laboratories L.C. | Phase 3 | Completed | Diarrhea | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01326338) |
| October 25, 2010 | NCT01227421 | Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza | Romark Laboratories L.C. | Phase 2/3 | Completed | Influenza | 624 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01227421) |
| January 26, 2010 | NCT01056380 | Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza | Romark Laboratories L.C. | Phase 2 | Terminated | Influenza | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01056380) |
| October 1, 2008 | NCT00763568 | 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C | Romark Laboratories L.C. | Phase 2 | Completed | Chronic Hepatitis C | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00763568) |
| March 18, 2008 | NCT00637923 | Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients | Romark Laboratories L.C. | Phase 2 | Completed | Chronic Hepatitis C | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00637923) |
| July 3, 2007 | NCT00495391 | Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C | Romark Laboratories L.C. | Phase 2 | Completed | Chronic Hepatitis C | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00495391) |
| January 12, 2007 | NCT00421434 | Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C | Romark Laboratories L.C. | Phase 2/3 | Completed | Chronic Hepatitis C | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00421434) |
| January 5, 2007 | NCT00418639 | Study of Nitazoxanide in the Treatment of Chronic Hepatitis C | Romark Laboratories L.C. | Phase 2 | Completed | Chronic Hepatitis C | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00418639) |
| January 4, 2007 | NCT00418054 | Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C | Romark Laboratories L.C. | Phase 2 | Completed | Chronic Hepatitis C | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00418054) |
| January 4, 2007 | NCT00417872 | Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis | Romark Laboratories L.C. | Phase 2 | Completed | Clostridium Difficile | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00417872) |
| October 6, 2006 | NCT00384527 | Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease | Romark Laboratories L.C. | Phase 3 | Terminated | Clostridium Infections | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00384527) |
| August 21, 2006 | NCT00366730 | Study of Nitazoxanide in the Treatment of Amebiasis in Children | Romark Laboratories L.C. | Phase 3 | Completed | Amebiasis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00366730) |
| August 21, 2006 | NCT00366236 | Study of Nitazoxanide in the Treatment of Amebiasis in Adults and Adolescents | Romark Laboratories L.C. | Phase 3 | Completed | Amebiasis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00366236) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 10 |
| Phase 2/3 | 3 |
| Phase 3 | 15 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Terminated | 6 |
| Withdrawn | 2 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis C, Chronic | 6 |
| Influenza, Human | 5 |
| COVID-19 | 5 |
| Enterovirus Infections | 2 |
| Cryptosporidiosis | 2 |
| HIV Infections | 2 |
| Diarrhea | 2 |
| Rotavirus Infections | 2 |
| Amebiasis | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Adenoviridae Infections | 1 |
| Caliciviridae Infections | 1 |
| Hepatitis B, Chronic | 1 |
| Hepatitis C | 1 |
| Gastroenteritis | 1 |
| Clostridium Infections | 1 |
| Crohn Disease | 1 |
| AIDS-Related Opportunistic Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Allergy and immunology practices in the United States](https://specstream.ai/data/businesses/allergy-and-immunology-practices/united-states)
- [Real estate investment firms in the United States](https://specstream.ai/data/businesses/real-estate-investment-firms/united-states)
- [Jewelry manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-manufacturers/united-states)
- [Door suppliers in the United States](https://specstream.ai/data/businesses/door-suppliers/united-states)
- [Assisted living facilities in the United States](https://specstream.ai/data/businesses/assisted-living-facilities/united-states)
